Real-World MI Risk Lower With NOACs vs Warfarin in AFib Real-World MI Risk Lower With NOACs vs Warfarin in AFib
The results, from a large registry, add to a growing body of evidence supporting the general safety of direct oral anticoagulants and may finally put to rest concerns about an MI signal with dabigatran.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Boehringer Ingelheim taps Medisafe for bundled Pradaxa offering
Medication management and adherence app maker Medisafe has announced a partnership with Boehringer Ingelheim following a successful pilot.   Medisafe will offer a wraparound app experience that incorporates Pradaxa-specific educational information into a special version of its app, which patients will be directed to when they're prescribed the drug. (Source: mobihealthnews)
Source: mobihealthnews - June 22, 2018 Category: Information Technology Source Type: news

Encouraging Early Safety Data for Dabigatran in Stroke Encouraging Early Safety Data for Dabigatran in Stroke
Results of a preliminary study show no increase in symptomatic hemorrhagic transformation with dabigatran vs aspirin in patients with TIA or minor stroke.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 30, 2018 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Vibrating ICD/CRT-D; Pradaxa Reversal Agent; Prevention Bonanza
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 23, 2018 Category: Urology & Nephrology Source Type: news

Dabigatran Antidote Praxbind Picks Up Full FDA Approval Dabigatran Antidote Praxbind Picks Up Full FDA Approval
Granted accelerated approval in 2015, the company now has received full FDA approval for idarucizumab to reverse the effects of dabigatran.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

FDA Provides Full Approval to Praxbind (idarucizumab), Specific Reversal Agent for Pradaxa
Ridgefield, Conn., April 17, 2018 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has provided full approval for Praxbind (idarucizumab), the specific reversal agent for Pradaxa (dabigatran etexilate... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2018 Category: Drugs & Pharmacology Source Type: news

Fewer Events on Dabigatran After Post-Noncardiac Surgery MI Fewer Events on Dabigatran After Post-Noncardiac Surgery MI
In the MANAGE trial, long-term dabigatran seemed protective in patients with the syndrome of myocardial injury after noncardiac surgery (MINS); observers debated just how to respond to the study.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 23, 2018 Category: Surgery Tags: Cardiology News Source Type: news

Another Way to Save a Life: the MANAGE Trial Another Way to Save a Life: the MANAGE Trial
Dr Walton-Shirley was impressed by a study on dabigatran for myocardial injury after noncardiac surgery at the American College of Cardiology Annual Scientific Session.theheart.org on Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Estudio de la FDA de pacientes de Medicare encontr ó menor riesgo de derrame cerebral y muerte con Pradaxa (dabigatrán) en comparación con warfarina
[05-13-2014] En su estudio en curso del anticoagulante Pradaxa (dabigatr án), la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus sigla en inglés) completó recientemente un nuevo estudio en pacientes de Medicare en el que compara Pradaxa con un anticoagulante antiguo, warfarina (Coumadin, Jantoven y genéricos), para determinar el riesgo de a ccidente isquémico o derrame causado por un coágulo, hemorragia cerebral, hemorragia gastrointestinal severa, infarto de miocardio y muerte. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin
[05-13-2014] In its ongoing review of the blood thinner Pradaxa (dabigatran), the U.S. Food and Drug Administration (FDA) recently completed a new study in Medicare patients comparing Pradaxa to an older blood thinner, warfarin, for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves
The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves, also known as mechanical prosthetic heart valves. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2018 Category: Drugs & Pharmacology Source Type: news

Dabigatran vs warfarin in NVAF: ERG risk score predicts cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Novel Antithrombotics and Lower Risk of Intraocular Bleeding Novel Antithrombotics and Lower Risk of Intraocular Bleeding
Novel antithrombotics such as dabigatran or rivaroxaban are associated, in some instances, with a decreased risk of intraocular hemorrhage compared with traditional anticoagulant therapy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Will new pill to stop a clot save me from a stroke?  
I have recently been prescribed Pradaxa to prevent clots and have been told there is a 3 per cent chance of me having a stroke. Is this a high risk, asks  Lionel Jenkins, New Zealand (Source: the Mail online | Health)
Source: the Mail online | Health - December 18, 2017 Category: Consumer Health News Source Type: news

Real-world Study Reassures on Dabigatran Stroke, ICH Rates Real-world Study Reassures on Dabigatran Stroke, ICH Rates
But results confirm gastrointestinal bleeding risk, particularly in the elderly and those with renal failure, and questions over the MI risk still remain.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 29, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New Data for Pradaxa ® and Praxbind® at AHA Scientific Sessions 2017
New Data for Pradaxa ® and Praxbind® at AHA Scientific Sessions 2017 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
Pradaxa ®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ®
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® data to be presented at the ESC Congress 2014
New Pradaxa ® data to be presented at the ESC Congress 2014 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) Video Statement
Pradaxa ® (dabigatran etexilate) Video Statement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New publication in The Lancet describes effective reversal of Pradaxa ® in healthy volunteers
New publication in The Lancet describes effective reversal of Pradaxa ® in healthy volunteers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim Presents New idarucizumab (Praxbind ®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
Boehringer Ingelheim Presents New idarucizumab (Praxbind ®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa ® in Routine Clinical Care
Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa ® in Routine Clinical Care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Praxbind ® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
Praxbind ® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New efficacy and safety data for Pradaxa ® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013
New efficacy and safety data for Pradaxa ® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® safety and efficacy data to be featured at ‘Best of ASH’ session
New Pradaxa ® safety and efficacy data to be featured at ‘Best of ASH’ session (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Treatment with Pradaxa ® associated with better patient outcomes after a major bleeding event compared to warfarin
Treatment with Pradaxa ® associated with better patient outcomes after a major bleeding event compared to warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
Pradaxa ® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Wealth of worldwide evidence on Pradaxa ® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions
Wealth of worldwide evidence on Pradaxa ® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations
Pradaxa ® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA and EMA reaffirm important health benefits and safety of Pradaxa ® (dabigatran etexilate) for patients with atrial fibrillation
FDA and EMA reaffirm important health benefits and safety of Pradaxa ® (dabigatran etexilate) for patients with atrial fibrillation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session
New Pradaxa ® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA approves Pradaxa ® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
FDA approves Pradaxa ® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Positive CHMP opinion for Pradaxa ® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots
Positive CHMP opinion for Pradaxa ® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New findings from two studies support substantial benefit of Pradaxa ® for prevention of recurrent deep vein thrombosis and pulmonary embolism
New findings from two studies support substantial benefit of Pradaxa ® for prevention of recurrent deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa ® compared to warfarin
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa ® compared to warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA perspective published in the  New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
FDA perspective published in the  New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa ® beyond 6 years
New long-term treatment data confirms consistent benefit and safety profile of Pradaxa ® beyond 6 years (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa ® (dabigatran etexilate) in expanded patient populations
Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa ® (dabigatran etexilate) in expanded patient populations (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do
Pradaxa ® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New long-term data reinforce safety profile of Pradaxa ® for stroke prevention in AF
New long-term data reinforce safety profile of Pradaxa ® for stroke prevention in AF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data analyses show consistent efficacy and safety profile of Pradaxa ® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
New data analyses show consistent efficacy and safety profile of Pradaxa ® in broad range of patients with acute deep vein thrombosis or pulmonary embolism* (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa ® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
Application submitted to the European Medicines Agency (EMA) for use of Pradaxa ® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

As the benefits and safety of Pradaxa ® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients
As the benefits and safety of Pradaxa ® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Antidote for rapid reversal of Pradaxa ® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
Antidote for rapid reversal of Pradaxa ® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism
New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Benefits of Pradaxa ® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
Benefits of Pradaxa ® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news